A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

To join this study, you generally need to have a solid tumour (meaning not a blood cancer) that has been checked by a doctor and can't be removed by surgery, has come back, or has spread to other parts of your body, and for which standard treatments aren't working well or you can't tolerate them. You must be at least 18 years old.

Depending on which part of the study you might join, you'll need to have a specific type of cancer. For example, some parts of the study are for people with certain kinds of kidney cancer that have been treated before but have gotten worse. Other parts are for people with a specific type of breast cancer (called hormone receptor positive and HER2 negative) that has spread or recurred after previous treatments.

The study also includes people with prostate cancer that has spread and is no longer responding to hormone therapy, as well as some patients with advanced bowel cancer. For bowel cancer, your tumour needs to have specific genetic features (KRAS/NRAS wild-type and not MSI-high/dMMR) and you need to have received certain standard chemotherapy treatments already.

Taking part in this study would involve regular visits to the hospital or clinic for check-ups, blood tests, and scans to see how your body is reacting to the treatment and whether the cancer is changing. You would be given the study drug, XL092, either on its own or along with one of the other study drugs (Atezolizumab or Avelumab), as decided by the study doctors. The exact schedule of visits and treatments would be explained in detail, but you can expect frequent monitoring in the beginning. The total length of your participation would depend on how your body responds to the treatment and if you experience side effects, but it could last for many months as long as the treatment is helping and you are tolerating it well.